Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
CC-292(一种高选择性布鲁顿酪氨酸激酶抑制剂)单药治疗复发/难治性慢性淋巴细胞白血病的I期研究
期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2015.140806
Brown, Jennifer R; Harb, Wael A; Hill, Brian T; Gabrilove, Janice; Sharman, Jeff P; Schreeder, Marshall T; Barr, Paul M; Foran, James M; Miller, Thomas P; Burger, Jan A; Kelly, Kevin R; Mahadevan, Daruka; Ma, Shuo; Li, Yan; Pierce, Daniel W; Barnett, Evelyn; Marine, Jeffrey; Miranda, Monika; Azaryan, Ada; Yu, Xujie; Nava-Parada, Pilar; Mei, Jay; Kipps, Thomas J